

Exploring the Potential of Ribociclib and Endocrine Therapy in Early Breast Cancer: Findings from the NATALEE Trial

Stephen Chia, M.D.

In this presentation, we will discuss the findings from the Phase III NATALEE trial which examined the combination of Ribociclib, at a 400mg starting dose, and endocrine therapy in patients with HR+/HER2- Early Breast Cancer (EBC). The trial showed an improved disease-free survival, indicating a reduction in the risk of invasive disease. The treatment also demonstrated benefits across various patient subgroups, and an improved distant disease-free survival. While overall survival improvement is not conclusive, further follow-up is in progress. Overall, the NATALEE trial results hint at the potential of Ribociclib combined with endocrine therapy as an advantageous treatment option for a broad population of stage II or III HR+/HER2- EBC patients at risk of recurrence.